Nanoviricides Inc (NNVC) Stock Price, Quote & News

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 937 6137

Website: www.nanoviricides.com

Address:

1 Controls Drive, Shelton, United States

DavidScott Jun. 16 at 3:40 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $VXRT $GEVO $GME $AMC $NNVC

0 · Reply

Love1010 Jun. 13 at 2:20 PM

$NNVC new downtrend to lower lows

0 · Reply

Love1010 Jun. 11 at 12:13 PM

$NNVC word on the street is not good

0 · Reply

STRAYNUT Jun. 10 at 9:08 PM

$NNVC Short Interest (05/30/25) Shares Sold Short 134,918 Change from Last 92.51% Percent of Float 0.87% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

Love1010 Jun. 5 at 12:32 PM

$NNVC once the reality settles in that Diwan has no intention of having results from humans, this stock will crash hard.

0 · Reply

Love1010 Jun. 4 at 9:38 PM

$NNVC diwan still kicking the can

0 · Reply

BondRevoked03 Jun. 4 at 5:14 PM

$NNVC 😁🚀🚀🚀🚀

0 · Reply

STRAYNUT Jun. 4 at 11:36 AM

$NNVC NanoViricides Measles Drug Development Animal Study is Imminent https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nanoviricides-measles-drug-development-animal-study-is-imminent-1035329

1 · Reply

DavinciTribeTrader Jun. 3 at 12:22 AM

Some of our latest winners: $MAIA - 1.90 to 2.74 - 44% profits $ATLX - 4 to 4.5 - 10% profits $TZUP - 5.91 to 9.74 - 60% profits $FMST - 1.11 to 4.18 - insane 376% PROFITS !!! (And it's still going) $NNVC - 1.00 to 1.79 - 79% profits Have an alert tomorrow. 8 AM EST SHARP ! Alert will be broadcasted on my DISCORD and TWITTER ONLY ! JOIN MY DISCORD/TWITTER by following the link in my bio.

0 · Reply

St0ckman691 Jun. 2 at 4:32 PM

$NNVC terrific Q3 update, lots in the pipeline to look forward to! https://finance.yahoo.com/news/nanoviricides-inc-filed-quarterly-report-103000270.html

0 · Reply

NanoViricides Measles Drug Development Animal Study is Imminent

May 28, 2025, 6:30 AM EDT - 20 days ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 22, 2025, 6:30 AM EDT - 26 days ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 14, 2025, 6:30 AM EDT - 4 weeks ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 5, 2025, 6:30 AM EDT - 6 weeks ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Apr 29, 2025, 6:30 AM EDT - 7 weeks ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 14, 2025, 6:30 AM EDT - 2 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Mar 11, 2025, 6:30 AM EDT - 3 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 4, 2025, 6:30 AM EST - 3 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Feb 19, 2025, 6:30 AM EST - 4 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 11, 2025, 6:30 AM EST - 4 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Jan 29, 2025, 6:30 AM EST - 4 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 27, 2025, 6:30 AM EST - 5 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 13, 2025, 6:30 AM EST - 5 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 8, 2025, 6:30 AM EST - 5 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Dec 23, 2024, 6:30 AM EST - 6 months ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Nov 15, 2024, 6:30 AM EST - 7 months ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 4, 2024, 12:00 AM EST - 8 months ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Oct 22, 2024, 6:30 AM EDT - 8 months ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 15, 2024, 6:30 AM EDT - 8 months ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 8, 2024, 6:30 AM EDT - 9 months ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Sep 30, 2024, 6:30 AM EDT - 9 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 26, 2024, 6:30 AM EDT - 9 months ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Aug 26, 2024, 7:30 AM EDT - 10 months ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 19, 2024, 6:30 AM EDT - 10 months ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 8, 2024, 6:30 AM EDT - 11 months ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Aug 2, 2024, 7:00 AM EDT - 11 months ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Aug 1, 2024, 6:30 AM EDT - 11 months ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Jul 24, 2024, 6:30 AM EDT - 11 months ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

Jul 11, 2024, 6:30 AM EDT - 1 year ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

Jun 24, 2024, 6:00 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

Jun 20, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Jun 11, 2024, 6:30 AM EDT - 1 year ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

Jun 4, 2024, 6:30 AM EDT - 1 year ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

May 20, 2024, 6:30 AM EDT - 1 year ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

May 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Has Filed its Quarterly Report

May 14, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

May 10, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

May 8, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

May 6, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

Apr 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

Feb 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

Feb 1, 2024, 6:20 AM EST - 1 year ago

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Jan 29, 2024, 6:30 AM EST - 1 year ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

Jan 4, 2024, 6:30 AM EST - 1 year ago

NanoViricides to Present at the Biotech Showcase in San Fransisco

Nov 28, 2023, 6:40 AM EST - 1 year ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

Nov 15, 2023, 6:45 AM EST - 1 year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

Nov 14, 2023, 6:45 AM EST - 1 year ago

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

Oct 16, 2023, 6:45 AM EDT - 1 year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV

Oct 12, 2023, 6:45 AM EDT - 1 year ago

NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET

DavidScott Jun. 16 at 3:40 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $VXRT $GEVO $GME $AMC $NNVC

0 · Reply

Love1010 Jun. 13 at 2:20 PM

$NNVC new downtrend to lower lows

0 · Reply

Love1010 Jun. 11 at 12:13 PM

$NNVC word on the street is not good

0 · Reply

STRAYNUT Jun. 10 at 9:08 PM

$NNVC Short Interest (05/30/25) Shares Sold Short 134,918 Change from Last 92.51% Percent of Float 0.87% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

Love1010 Jun. 5 at 12:32 PM

$NNVC once the reality settles in that Diwan has no intention of having results from humans, this stock will crash hard.

0 · Reply

Love1010 Jun. 4 at 9:38 PM

$NNVC diwan still kicking the can

0 · Reply

BondRevoked03 Jun. 4 at 5:14 PM

$NNVC 😁🚀🚀🚀🚀

0 · Reply

STRAYNUT Jun. 4 at 11:36 AM

1 · Reply

DavinciTribeTrader Jun. 3 at 12:22 AM

0 · Reply

St0ckman691 Jun. 2 at 4:32 PM

$NNVC terrific Q3 update, lots in the pipeline to look forward to! https://finance.yahoo.com/news/nanoviricides-inc-filed-quarterly-report-103000270.html

0 · Reply

Stockprofiler Jun. 2 at 3:53 PM

$NNVC NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. www.nanoviricides.com

0 · Reply

Stockprofiler Jun. 2 at 3:04 PM

$NNVC up early! (NYSE Amer.:NNVC ) The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan https://finance.yahoo.com/news/rational-fda-covid-vaccine-policy-103000219.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr @St0ckman691 @NYSE

0 · Reply

St0ckman691 Jun. 2 at 2:30 PM

$NNVC looks like bottom secured on the daily chart, bounce time:

0 · Reply

Stockprofiler Jun. 2 at 2:04 PM

$NNVC 1.5693 +3.93% NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 https://finance.yahoo.com/news/nanoviricides-present-bio-international-convention-103000913.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

0 · Reply

St0ckman691 Jun. 2 at 1:14 PM

$NNVC "Bind-Engulf-Destroy" Viruses: https://www.nanoviricides.com/technology

0 · Reply

Stockprofiler Jun. 2 at 12:10 PM

$NNVC NanoViricides Inc. (NASDAQ: NNVC) just cleared major resistance after a strong rally from the $1 level. In this quick technical breakdown, we explore why the $1.50 zone is now critical—and what it could mean for the next leg up. https://www.youtube.com/watch?v=bljUTYf2AJw

0 · Reply

St0ckman691 Jun. 2 at 12:06 PM

$NNVC Big stage for them on June 16th - wouldn't surprise me to see some news ahead of this convention! https://finance.yahoo.com/news/nanoviricides-present-bio-international-convention-103000913.html

0 · Reply

St0ckman691 Jun. 2 at 11:58 AM

$NNVC watching closely here, bullish chart! https://youtu.be/bljUTYf2AJw?si=LroeGsr5kFZp0ip2

0 · Reply

Love1010 May. 29 at 10:23 PM

$NNVC Dangerous technical analysis. End the month with a long upper wick. Always bearish for this stock.

0 · Reply

Jpextreme1 May. 28 at 3:45 PM

$NNVC This nice Adds

0 · Reply

STRAYNUT May. 28 at 12:25 AM

$NNVC Short Interest (05/15/25) Shares Sold Short 70,084 Change from Last -46.27% Percent of Float 0.45% https://www.wsj.com/market-data/quotes/NNVC

1 · Reply

DayTradingPredictions May. 27 at 6:26 PM

$NNVC NNVC :

0 · Reply

Market Cap	24.27M
Revenue (ttm)	0.00
Net Income (ttm)	-8.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	224,800
Avg Vol	175,504
Day's Range	N/A - N/A
Shares Out	16.07M
Stochastic %K	0%
Beta	0.91
Analysts	Strong Sell
Price Target	$6.50